<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530476</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0975</org_study_id>
    <secondary_id>NCI-2015-01523</secondary_id>
    <secondary_id>P50CA100632</secondary_id>
    <nct_id>NCT02530476</nct_id>
  </id_info>
  <brief_title>Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion).&#xD;
&#xD;
      The goal of Part 1 of this clinical research study is to find the highest tolerated dose of&#xD;
      the combination of selinexor (KPT-330) and sorafenib (Nexavar) that can be given to patients&#xD;
      with FLT3-ITD and -D835 mutated acute myeloid leukemia (AML) or FLT3-mutated high-risk&#xD;
      myelodysplastic syndrome (MDS).&#xD;
&#xD;
      The goal of Part 2 of this study is to learn if the dose found in Part 1 can help to control&#xD;
      the disease.&#xD;
&#xD;
      The safety of the drug combination will also be studied in both parts of this study.&#xD;
&#xD;
      This is an investigational study. Sorafenib is FDA approved and commercially available to&#xD;
      treat hepatocellular cancer. Selinexor is not FDA approved or commercially available. It is&#xD;
      currently being used for research purposes only. The combination of selinexor and sorafenib&#xD;
      to treat FLT3-mutated AML and high-risk MDS is investigational.&#xD;
&#xD;
      The study doctor can explain how the study drugs are designed to work.&#xD;
&#xD;
      Up to 52 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 3 groups of up to 6 participants will be&#xD;
      enrolled in Part 1 of the study, and up to 40 participants will be enrolled in Part 2.&#xD;
&#xD;
      If you are enrolled in Part 1, the dose of selinexor and sorafenib you receive will depend on&#xD;
      when you joined this study. The first group of participants will receive the starting dose&#xD;
      combination level. If no intolerable side effects were seen, the next group will receive a&#xD;
      higher dose of selinexor and sorafenib than Group 1. If intolerable side effects are seen,&#xD;
      the next group may receive a lower dose level of selinexor and/or sorafenib. This will&#xD;
      continue until the highest tolerable combination dose is found.&#xD;
&#xD;
      If you are enrolled in Part 2, you will receive selinexor and sorafenib at the highest&#xD;
      tolerable combination dose or most effective combination dose found in Part 1.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      Each study cycle is 28 days. However, the study cycles may be 3-12 weeks long, depending on&#xD;
      if/how the disease responds to the treatment, how your bone marrow reacts to treatment, and&#xD;
      what the doctor thinks is in your best interest.&#xD;
&#xD;
      You will take selinexor tablets by mouth 2 times each week (Monday/Wednesday or&#xD;
      Tuesday/Thursday or Wednesday/Friday) for 3 weeks. You must take your dose of selinexor&#xD;
      within 30 minutes after eating, with at least 4 ounces of fluids (either water, milk, juice,&#xD;
      and so on). You must swallow the tablets whole. Do not crush them. If the powder comes into&#xD;
      contact with your skin, you may have an increased chance of skin-related side effects.&#xD;
&#xD;
      You will take sorafenib by mouth 2 times a day, every day. Depending on how the disease&#xD;
      responds to the study drugs, the number of days you receive the study drug may change. Your&#xD;
      doctor will discuss this with you. You must take your dose of sorafenib at least 1 hour&#xD;
      before or 1 hour after eating.&#xD;
&#xD;
      You will be given a drug diary and asked to write down what time you take the study drugs&#xD;
      every day. You must bring in the study drug diary and any unused study drugs and bottles to&#xD;
      each study visit.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of Cycles 1-4 and then every 1-3 cycles after that:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
&#xD;
      The study doctor will tell you how often you will have these tests after Cycle 4.&#xD;
&#xD;
      One time each week during Cycles 1-3, blood (about 1 tablespoon) will be drawn for routine&#xD;
      tests. After Cycle 3, you will have this blood draw 1 time every 2-4 weeks. If the doctor&#xD;
      thinks it is needed, blood may need to be drawn more often or more than 1 tablespoon of blood&#xD;
      may need to be drawn.&#xD;
&#xD;
      After Cycle 1, you may be able to have these blood draws performed at a local lab or clinic&#xD;
      that is closer to your home. The results of the testing will be sent to MD Anderson for&#xD;
      review. The study doctor or study staff will discuss this option with you.&#xD;
&#xD;
      On Day 28 of Cycles 1 and 3 (+/- 7 days) and then every 1-3 cycles after that, you will have&#xD;
      a bone marrow aspiration and/or biopsy to check the status of the disease.&#xD;
&#xD;
      Every 3 months (+/- 14 days), if you can become pregnant, blood (about 1-2 tablespoons) or&#xD;
      urine will be collected for a pregnancy test.&#xD;
&#xD;
      If you stay on study for more than 6 months and you are not having side effects, you may have&#xD;
      some of the above tests more or less often. The study doctor will discuss this with you.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drugs for as long as the study doctor thinks it is in your&#xD;
      best interest. You will no longer be able to take the study drugs if the disease gets worse,&#xD;
      if intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the follow-up visits.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      If you stop taking the study drugs before the end of Cycle 24:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a bone marrow aspirate to check the&#xD;
           status of the disease.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      About 30 days (+/- 7) after your last dose of study drugs, you will have a physical exam. You&#xD;
      may have this exam at MD Anderson or a local clinic near your home. If you have this exam at&#xD;
      a local clinic, the results of the exam will be sent to MD Anderson for review.&#xD;
&#xD;
      If you cannot come to MD Anderson or a local clinic, you will be called by a member of the&#xD;
      study staff and asked if you have had any side effects and/or started any new treatment(s).&#xD;
      This call should last about 5 minutes.&#xD;
&#xD;
      Long-Term Follow-Up:&#xD;
&#xD;
      If the disease appears to get better and you are responding well to the study drug, you will&#xD;
      return to MD Anderson every 3-6 months for up to 5 years after your last dose of study drugs&#xD;
      for the study staff to check how you are doing.&#xD;
&#xD;
      If you cannot return to MD Anderson for these visits, you may be called by a member of the&#xD;
      study staff. The call should last about 10 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <completion_date type="Actual">April 8, 2019</completion_date>
  <primary_completion_date type="Actual">April 8, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Selinexor With Sorafenib</measure>
    <time_frame>28 days</time_frame>
    <description>MTD defined as the highest dose level with &lt;/= 1 out of 6 patients experience a dose limiting toxicity (DLT) during the first 28 days of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite CR (CRc) Rate Defined as CR (Complete Remission) + CRp (Complete Remission With Incomplete Platelet Recovery) + CRi (Complete Remission With Incomplete Count Recovery) Within 3 Months of Treatment Initiation</measure>
    <time_frame>84 days, assessed following first three cycles of therapy of Selinexor with Sorafenib</time_frame>
    <description>CRc Response criteria modified from International Working Group for AML. Responders obtain a Composite Complete Remission Rate (CRc) with or without cytogenetic response, hematologic improvements, and morphologic leukemia-free state. CRc rate is defined as the confirmed remission rate of all complete and incomplete CRs (i.e., CR+ CRp + CRi).&#xD;
CR: bone marrow regenerating normal hematopoietic cells &amp; morphologic leukemia-free state, &amp; ANC &gt; 1×10^9/L, platelet count ≥100×10^9/L, &amp; normal marrow differential with &lt;5% blasts, &amp; red blood cell (RBC) and platelet transfusion independent, no evidence of extramedullary leukemia. CRp: CR except for incomplete platelet recovery (&lt;100×10^9/L). CRi: Same criteria for CR except incomplete hematological recovery with residual neutropenia (ANC ≤ 1 × 109/L) with or without thrombocytopenia (platelet count &lt;100×109/L). No need to be RBC or platelet transfusion independent (modification to Cheson criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 15 months, on average 5 months</time_frame>
    <description>Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase I Group 1 Selinexor + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 (FLT3-ITD inhibitor failure cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (FLT3-ITD inhibitor naive cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Group 2 Selinexor + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.</description>
    <arm_group_label>Cohort 1 (FLT3-ITD inhibitor failure cohort)</arm_group_label>
    <arm_group_label>Cohort 2 (FLT3-ITD inhibitor naive cohort)</arm_group_label>
    <arm_group_label>Phase I Group 1 Selinexor + Sorafenib</arm_group_label>
    <arm_group_label>Phase I Group 2 Selinexor + Sorafenib</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
    <arm_group_label>Cohort 1 (FLT3-ITD inhibitor failure cohort)</arm_group_label>
    <arm_group_label>Cohort 2 (FLT3-ITD inhibitor naive cohort)</arm_group_label>
    <arm_group_label>Phase I Group 1 Selinexor + Sorafenib</arm_group_label>
    <arm_group_label>Phase I Group 2 Selinexor + Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. FLT3-ITD and/or FLT3-D835 mutated patients 18 years of age or older with relapsed/&#xD;
             refractory AML (any number of relapses) including patients who may have been&#xD;
             previously exposed to one or more FLT3-inhibitor therapies will be eligible for the&#xD;
             phase I portion of this study.&#xD;
&#xD;
          2. Phase II FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory patients: Patients&#xD;
             should have a diagnosis of AML (de novo or transformed from hematologic malignancies).&#xD;
             Patients with high-risk myelodysplastic syndrome (MDS) (defined as having &gt;/= 10%&#xD;
             blasts in the bone marrow) or patients with Chronic Myelomonocytic Leukemia (CMML)&#xD;
             (having &gt;/= 10% blasts in the bone marrow) may also be eligible after discussion with&#xD;
             Principal Investigator (PI). The patients should have one of the following features:&#xD;
             1. Patients with AML should have failed any prior induction therapy or have relapsed&#xD;
             after prior therapy. 2. Patients with high-risk MDS or high-risk CMML should have&#xD;
             failed any prior therapy for the MDS or CMML. 3. Patients with MDS or CMML who&#xD;
             received therapy for the MDS or CMML and progress to AML are eligible at the time of&#xD;
             diagnosis of AML regardless any prior therapy for AML. The World Health Organization&#xD;
             (WHO) classification will be used for AML.&#xD;
&#xD;
          3. Patients must be eligible for one of two cohorts: Cohort 1 (FLT3 and/or FLT3-D835&#xD;
             inhibitor failure cohort) in FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory AML&#xD;
             who have failed therapy with up to two prior salvage regimens (SCT or stem cell&#xD;
             therapy for patients who previously underwent SCT/stem cell therapy in remission will&#xD;
             not be considered a salvage regimen) and have previously been exposed at least one&#xD;
             prior FLT3 inhibitor. Cohort 2 (FLT3 inhibitor naive cohort) in FLT3-ITD and/or&#xD;
             FLT3-D835 mutated relapsed/refractory who have failed therapy with up to two prior&#xD;
             salvage regimens (SCT or stem cell therapy for patients who previously underwent&#xD;
             SCT/stem cell therapy in remission will not be considered a salvage regimen) with no&#xD;
             prior exposure to any FLT3 inhibitor.&#xD;
&#xD;
          4. Age &gt;/=18 years&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;/=2&#xD;
&#xD;
          6. Patients should have estimated life expectancy of &gt;3 months at study entry&#xD;
&#xD;
          7. Adequate hepatic (serum total bilirubin &lt;/= 2.0 x upper limit normal (ULN) (or &lt;/= 3.0&#xD;
             x ULN if deemed to be elevated due to leukemia), alanine aminotransferase and/or&#xD;
             aspartate transaminase &lt;/= 3.0 x ULN (or &lt;/= 5.0 x ULN if deemed to be elevated due to&#xD;
             leukemia), and renal function (creatinine &lt;/= 2.0 mg/dL).&#xD;
&#xD;
          8. Patients must provide written informed consent.&#xD;
&#xD;
          9. In the absence of rapidly progressing disease, the interval from prior treatment to&#xD;
             time of initiation of selinexor and sorafenib administration will be at least 2 weeks&#xD;
             for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents. The&#xD;
             use of chemotherapeutic or anti-leukemic agents is not permitted during the study with&#xD;
             the following exceptions: (1) intrathecal (IT) therapy for patients with controlled&#xD;
             Central Nervous System (CNS) leukemia at the discretion of the PI and with the&#xD;
             agreement of the Sponsor. Controlled CNS leukemia is defined by the absence of active&#xD;
             clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2&#xD;
             simultaneous CSF evaluations. (2) Use of one dose of cytarabine (up to 2 g/m2) or&#xD;
             hydroxyurea for patients with rapidly proliferative disease is allowed before the&#xD;
             start of study therapy and for the first four weeks on therapy. These medications will&#xD;
             be recorded in the case-report form.&#xD;
&#xD;
         10. Baseline ejection fraction must be &gt;/= 40%.&#xD;
&#xD;
         11. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for&#xD;
             at least 12 months) or if of childbearing potential, must have a negative serum or&#xD;
             urine pregnancy test within 72 hours before the start of the treatment.&#xD;
&#xD;
         12. Women of childbearing potential must agree to use an adequate method of contraception&#xD;
             during the study and until 3 months after the last treatment. Males must be surgically&#xD;
             or biologically sterile or agree to use an adequate method of contraception during the&#xD;
             study until 3 months after the last treatment. Adequate methods of contraception&#xD;
             include: Total abstinence when this is in line with the preferred and usual lifestyle&#xD;
             of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
             post-ovulation methods) and withdrawal are not acceptable methods of contraception.&#xD;
             Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
             hysterectomy) or tubal ligation at least six weeks before taking study treatment. In&#xD;
             case of oophorectomy alone, only when the reproductive status of the woman has been&#xD;
             confirmed by follow up hormone level assessment&#xD;
&#xD;
         13. (Continued from Criteria 12) Male sterilization (at least 6 months prior to&#xD;
             screening). For female patients on the study, the vasectomized male partner should be&#xD;
             the sole partner for that patient Combination of any of the two following (a+b or a+c&#xD;
             or b+c) Use of oral, injected or implanted hormonal methods of contraception or other&#xD;
             forms of hormonal contraception that have comparable efficacy (failure rate &lt;1%), for&#xD;
             example hormone vaginal ring or transdermal hormone contraception Placement of an&#xD;
             intrauterine device (IUD) or intrauterine system (IUS) Barrier methods of&#xD;
             contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with&#xD;
             spermicidal foam/gel/film/cream/ vaginal suppository&#xD;
&#xD;
         14. (Continued from Criteria 13) In case of use of oral contraception, women should have&#xD;
             been stable on the same pill before taking study treatment. Note: Oral contraceptives&#xD;
             are allowed but should be used in conjunction with a barrier method of contraception&#xD;
             due to unknown effect of drug-drug interaction. Women are considered post-menopausal&#xD;
             and not of child bearing potential if they have had 12 months of natural (spontaneous)&#xD;
             amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of&#xD;
             vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without&#xD;
             hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy&#xD;
             alone, only when the reproductive status of the woman has been confirmed by follow up&#xD;
             hormone level assessment is she considered not of child bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its&#xD;
             components.&#xD;
&#xD;
          2. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or&#xD;
             psychiatric illness, which could place him/her at unacceptable risk.&#xD;
&#xD;
          3. Patients who have had any major surgical procedure within 14 days of Day 1.&#xD;
&#xD;
          4. Patients currently receiving any other standard or investigational therapy for the&#xD;
             treatment of AML.&#xD;
&#xD;
          5. Patients unwilling or unable to comply with the protocol.&#xD;
&#xD;
          6. Patients receiving concomitant treatment with strong CYP3A4 inhibitors, unless such&#xD;
             drugs are considered critical for the well being of the patient and not adequate&#xD;
             alternatives are available. Strong CYP3A4 inhibitors include the following&#xD;
             medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir,&#xD;
             atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin,&#xD;
             clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone,&#xD;
             nicardipine, propofol, quinidine, telithromycin.&#xD;
&#xD;
          7. Patients with any severe gastrointestinal or metabolic condition that could interfere&#xD;
             with absorption of oral medications.&#xD;
&#xD;
          8. Patients who are in blast transformation of chronic myeloid leukemia (CML). Prior MDS&#xD;
             or CMML is acceptable.&#xD;
&#xD;
          9. Patient has a concurrent active malignancy under treatment.&#xD;
&#xD;
         10. Unstable cardiovascular function: • Symptomatic ischemia, or • Uncontrolled clinically&#xD;
             significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic&#xD;
             agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left&#xD;
             anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded),&#xD;
             or • Congestive heart failure (CHF) New York Heart Association (NYHA) Class ≥ 3, or •&#xD;
             Myocardial infarction (MI) within 3 months. • Left ventricular ejection fraction &lt; 40&#xD;
             %. • Hypertension &gt; 140 mm Hg systolic or &gt; 90 mm Hg diastolic with or without&#xD;
             antihypertensive therapy.&#xD;
&#xD;
         11. Uncontrolled infection at the time of enrollment. Infections controlled on concurrent&#xD;
             anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional&#xD;
             guidelines is acceptable.&#xD;
&#xD;
         12. Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be&#xD;
             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).&#xD;
&#xD;
         13. Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         14. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
         15. Acute promyelocytic leukemia.&#xD;
&#xD;
         16. Any medical condition, which in the investigator's opinion, could compromise the&#xD;
             patient's safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval Daver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2015</study_first_posted>
  <results_first_submitted>February 21, 2020</results_first_submitted>
  <results_first_submitted_qc>March 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2020</results_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>FLT3-ITD mutation</keyword>
  <keyword>FLT3-mutated high-risk myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>Selinexor</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Nexavar</keyword>
  <keyword>BAY 43-9006</keyword>
  <keyword>FLT3-inhibitor therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02530476/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 2015 to July 2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Group 1 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="P2">
          <title>Phase I Group 2 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I Group 1 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="B2">
          <title>Phase I Group 2 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.5" lower_limit="24" upper_limit="81"/>
                    <measurement group_id="B2" value="68" lower_limit="68" upper_limit="74"/>
                    <measurement group_id="B3" value="63" lower_limit="38" upper_limit="75"/>
                    <measurement group_id="B4" value="77" lower_limit="31" upper_limit="79"/>
                    <measurement group_id="B5" value="68" lower_limit="24" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Selinexor With Sorafenib</title>
        <description>MTD defined as the highest dose level with &lt;/= 1 out of 6 patients experience a dose limiting toxicity (DLT) during the first 28 days of treatment.</description>
        <time_frame>28 days</time_frame>
        <population>The Outcome Measure of MTD was the objective of the Phase I Selinexor + Sorafenib cohort only. Data for MTD were not collected for patients on Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Group 1 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Group 2 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Selinexor With Sorafenib</title>
          <description>MTD defined as the highest dose level with &lt;/= 1 out of 6 patients experience a dose limiting toxicity (DLT) during the first 28 days of treatment.</description>
          <population>The Outcome Measure of MTD was the objective of the Phase I Selinexor + Sorafenib cohort only. Data for MTD were not collected for patients on Cohorts 1 and 2.</population>
          <units>Milligrams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite CR (CRc) Rate Defined as CR (Complete Remission) + CRp (Complete Remission With Incomplete Platelet Recovery) + CRi (Complete Remission With Incomplete Count Recovery) Within 3 Months of Treatment Initiation</title>
        <description>CRc Response criteria modified from International Working Group for AML. Responders obtain a Composite Complete Remission Rate (CRc) with or without cytogenetic response, hematologic improvements, and morphologic leukemia-free state. CRc rate is defined as the confirmed remission rate of all complete and incomplete CRs (i.e., CR+ CRp + CRi).&#xD;
CR: bone marrow regenerating normal hematopoietic cells &amp; morphologic leukemia-free state, &amp; ANC &gt; 1×10^9/L, platelet count ≥100×10^9/L, &amp; normal marrow differential with &lt;5% blasts, &amp; red blood cell (RBC) and platelet transfusion independent, no evidence of extramedullary leukemia. CRp: CR except for incomplete platelet recovery (&lt;100×10^9/L). CRi: Same criteria for CR except incomplete hematological recovery with residual neutropenia (ANC ≤ 1 × 109/L) with or without thrombocytopenia (platelet count &lt;100×109/L). No need to be RBC or platelet transfusion independent (modification to Cheson criteria).</description>
        <time_frame>84 days, assessed following first three cycles of therapy of Selinexor with Sorafenib</time_frame>
        <population>Of the four participants in the Phase I Group 1 Selinexor + Sorafenib arm, one participant was not evaluable for response. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Group 1 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Group 2 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite CR (CRc) Rate Defined as CR (Complete Remission) + CRp (Complete Remission With Incomplete Platelet Recovery) + CRi (Complete Remission With Incomplete Count Recovery) Within 3 Months of Treatment Initiation</title>
          <description>CRc Response criteria modified from International Working Group for AML. Responders obtain a Composite Complete Remission Rate (CRc) with or without cytogenetic response, hematologic improvements, and morphologic leukemia-free state. CRc rate is defined as the confirmed remission rate of all complete and incomplete CRs (i.e., CR+ CRp + CRi).&#xD;
CR: bone marrow regenerating normal hematopoietic cells &amp; morphologic leukemia-free state, &amp; ANC &gt; 1×10^9/L, platelet count ≥100×10^9/L, &amp; normal marrow differential with &lt;5% blasts, &amp; red blood cell (RBC) and platelet transfusion independent, no evidence of extramedullary leukemia. CRp: CR except for incomplete platelet recovery (&lt;100×10^9/L). CRi: Same criteria for CR except incomplete hematological recovery with residual neutropenia (ANC ≤ 1 × 109/L) with or without thrombocytopenia (platelet count &lt;100×109/L). No need to be RBC or platelet transfusion independent (modification to Cheson criteria).</description>
          <population>Of the four participants in the Phase I Group 1 Selinexor + Sorafenib arm, one participant was not evaluable for response. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
        <time_frame>Up to 15 months, on average 5 months</time_frame>
        <population>Overall Survival was not an objective outlined for participants in Phase I Group's 1 and 2, therefore overall survival was not done for these participants. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Group 1 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Group 2 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
          <population>Overall Survival was not an objective outlined for participants in Phase I Group's 1 and 2, therefore overall survival was not done for these participants. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.5" lower_limit="0.9" upper_limit="14"/>
                    <measurement group_id="O4" value="2.3" lower_limit="0.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival</title>
        <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>Event Free Survival was not an objective outlined for participants in Phase I Group's 1 and 2, therefore overall survival was not done for these participants. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Group 1 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Group 2 Selinexor + Sorafenib</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
            <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival</title>
          <description>Time from date of treatment start until the date of first objective documentation of disease-relapse.</description>
          <population>Event Free Survival was not an objective outlined for participants in Phase I Group's 1 and 2, therefore overall survival was not done for these participants. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.8" lower_limit="0.4" upper_limit="5.0"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.7" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I Group 1 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="E2">
          <title>Phase I Group 2 Selinexor + Sorafenib</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.&#xD;
Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)</title>
          <description>Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Selinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.&#xD;
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.&#xD;
Sorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.&#xD;
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorders Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Administration Site Conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness Lower Limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and Unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naval Daver, MD/Associate Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-794-4392</phone>
      <email>NDaver@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

